Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Non-Current Liabilities: 2015-2025

Historic Other Non-Current Liabilities for Aytu Biopharma (AYTU) over the last 11 years, with Sep 2025 value amounting to $20.4 million.

  • Aytu Biopharma's Other Non-Current Liabilities rose 117.23% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 117.23%. This contributed to the annual value of $26.3 million for FY2025, which is 106.62% up from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Other Non-Current Liabilities is $20.4 million, which was down 22.44% from $26.3 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Other Non-Current Liabilities registered a high of $26.3 million during Q2 2025, and its lowest value of $4.9 million during Q1 2025.
  • Over the past 3 years, Aytu Biopharma's median Other Non-Current Liabilities value was $9.4 million (recorded in 2024), while the average stood at $11.7 million.
  • In the last 5 years, Aytu Biopharma's Other Non-Current Liabilities crashed by 67.06% in 2022 and then soared by 117.23% in 2025.
  • Aytu Biopharma's Other Non-Current Liabilities (MRQ) stood at $8.3 million in 2021, then rose by 17.89% to $9.8 million in 2022, then skyrocketed by 31.76% to $12.9 million in 2023, then plummeted by 50.45% to $6.4 million in 2024, then surged by 219.82% to $20.4 million in 2025.
  • Its last three reported values are $20.4 million in Q3 2025, $26.3 million for Q2 2025, and $4.9 million during Q1 2025.